Company profile: Trius Therapeutics
1.1 - Company Overview
Company description
- Provider of discovery, development and commercialization of innovative antibiotics for life-threatening infections. Completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI, with IV and orally administered formulations.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Trius Therapeutics
Humanigen
HQ: United States
Website
- Description: Provider of biopharmaceutical development focused on human antibody therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Humanigen company profile →
AdvanDx
HQ: United States
Website
- Description: Provider of rapid and accurate molecular in vitro diagnostic tests and kits for identifying pathogens causing critical infections in hospitalized patients, enabling healthcare providers to optimize antibiotic therapy earlier to improve patient outcomes while limiting unnecessary antibiotic use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AdvanDx company profile →
Ansun BioPharma
HQ: United States
Website
- Description: Provider of host-directed antivirals and solid tumor therapies. Offers DAS181, a recombinant sialidase that removes sialic acids from respiratory epithelial cells to block viral entry and treat parainfluenza and influenza. Develops multi-modality platforms targeting tumor and immune cells to prevent immune escape and restore tumor surveillance, including oncolytic viruses, bispecific antibodies, and CAR-NK/γδ T cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ansun BioPharma company profile →
Gritstone Bio
HQ: United States
Website
- Description: Provider of immunotherapies for cancer and infectious diseases, including GRANITE, a personalized neoantigen vaccine for solid tumors; SLATE, an off-the-shelf shared-neoantigen immunotherapy for KRAS-driven tumors; CORAL, prophylactic vaccines using self-amplifying mRNA; an HIV vaccine collaboration with Gilead; and EDGE, an AI platform to identify T cell targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gritstone Bio company profile →
PBD Biotech
HQ: United Kingdom
Website
- Description: Provider of clinical-stage phage-based diagnostics for tuberculosis, developing Actiphage TB, a blood-based test that detects Mycobacterium tuberculosis, supporting latent TB screening, active infection detection, and drug management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PBD Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Trius Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Trius Therapeutics
2.2 - Growth funds investing in similar companies to Trius Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Trius Therapeutics
4.2 - Public trading comparable groups for Trius Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →